Loading...

We've got a brand new version of Simply Wall St! Try it out

Anatara Lifesciences

ASX:ANR
Snowflake Description

Exceptional growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANR
ASX
A$11M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastro intestinal diseases in animals and humans in Australia. The last earnings update was 84 days ago. More info.


Add to Portfolio Compare Print
  • Anatara Lifesciences has significant price volatility in the past 3 months.
ANR Share Price and Events
7 Day Returns
-11.4%
ASX:ANR
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-59.8%
ASX:ANR
50.9%
AU Biotechs
16.3%
AU Market
ANR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anatara Lifesciences (ANR) -11.4% -7.1% -15.2% -59.8% -82.1% -40%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • ANR underperformed the Biotechs industry which returned 50.9% over the past year.
  • ANR underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
ANR
Industry
5yr Volatility vs Market

ANR Value

 Is Anatara Lifesciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Anatara Lifesciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Anatara Lifesciences.

ASX:ANR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:ANR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.28 (1 + (1- 30%) (0%))
1.188
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.19
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.188 * 5.96%)
9.39%

Discounted Cash Flow Calculation for ASX:ANR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Anatara Lifesciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

ASX:ANR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.39%)
2020 -1.10 Analyst x1 -1.01
2021 1.30 Analyst x1 1.09
2022 6.80 Analyst x1 5.19
2023 20.70 Analyst x1 14.46
2024 32.20 Analyst x1 20.56
2025 41.42 Est @ 28.63% 24.17
2026 50.01 Est @ 20.74% 26.68
2027 57.62 Est @ 15.21% 28.10
2028 64.15 Est @ 11.34% 28.60
2029 69.69 Est @ 8.63% 28.40
Present value of next 10 years cash flows A$176.00
ASX:ANR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$69.69 × (1 + 2.31%) ÷ (9.39% – 2.31%)
A$1,007.10
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$1,007.10 ÷ (1 + 9.39%)10
A$410.43
ASX:ANR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$176.00 + A$410.43
A$586.43
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$586.43 / 49.56
A$11.83
ASX:ANR Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$11.83
Current discount Discount to share price of A$0.20
= -1 x (A$0.20 - A$11.83) / A$11.83
98.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Anatara Lifesciences is available for.
Intrinsic value
>50%
Share price is A$0.2 vs Future cash flow value of A$11.83
Current Discount Checks
For Anatara Lifesciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Anatara Lifesciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Anatara Lifesciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anatara Lifesciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anatara Lifesciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ANR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.06
ASX:ANR Share Price ** ASX (2019-11-17) in AUD A$0.2
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anatara Lifesciences.

ASX:ANR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ANR Share Price ÷ EPS (both in AUD)

= 0.2 ÷ -0.06

-3.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anatara Lifesciences is loss making, we can't compare its value to the Global Biotechs industry average.
  • Anatara Lifesciences is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Anatara Lifesciences's expected growth come at a high price?
Raw Data
ASX:ANR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
65.6%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anatara Lifesciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anatara Lifesciences's assets?
Raw Data
ASX:ANR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.12
ASX:ANR Share Price * ASX (2019-11-17) in AUD A$0.2
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:ANR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ANR Share Price ÷ Book Value per Share (both in AUD)

= 0.2 ÷ 0.12

1.63x

* Primary Listing of Anatara Lifesciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anatara Lifesciences is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Anatara Lifesciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anatara Lifesciences has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ANR Future Performance

 How is Anatara Lifesciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anatara Lifesciences expected to grow at an attractive rate?
  • Anatara Lifesciences's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Anatara Lifesciences's earnings growth is expected to exceed the Australia market average.
  • Anatara Lifesciences's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:ANR Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:ANR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 65.6%
ASX:ANR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 51.2%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ANR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ANR Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-06-30 36 32 31 1
2023-06-30 25 21 19 1
2022-06-30 12 7 6 1
2021-06-30 6 2 1 1
2020-06-30 3 -1 -1 1
2019-11-18
ASX:ANR Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -2 -3
2019-03-31 0 -3 -3
2018-12-31 1 -2 -4
2018-09-30 1 -3 -4
2018-06-30 0 -3 -4
2018-03-31 1 -3 -3
2017-12-31 2 -3 -3
2017-09-30 2 -3 -2
2017-06-30 3 -3 -2
2017-03-31 4 -2 -1
2016-12-31 4 -1 0
2016-09-30 3 -1 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Anatara Lifesciences's earnings are expected to grow significantly at over 20% yearly.
  • Anatara Lifesciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ANR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Anatara Lifesciences Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ANR Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-06-30 0.60 0.60 0.60 1.00
2023-06-30 0.38 0.38 0.38 1.00
2022-06-30 0.12 0.12 0.12 1.00
2021-06-30 0.02 0.02 0.02 1.00
2020-06-30 -0.02 -0.02 -0.02 1.00
2019-11-18
ASX:ANR Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.06
2019-03-31 -0.07
2018-12-31 -0.08
2018-09-30 -0.08
2018-06-30 -0.07
2018-03-31 -0.07
2017-12-31 -0.06
2017-09-30 -0.05
2017-06-30 -0.03
2017-03-31 -0.02
2016-12-31 0.00
2016-09-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Anatara Lifesciences is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Anatara Lifesciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anatara Lifesciences has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ANR Past Performance

  How has Anatara Lifesciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anatara Lifesciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anatara Lifesciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Anatara Lifesciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Anatara Lifesciences's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Anatara Lifesciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anatara Lifesciences Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ANR Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.66 -2.87 3.78
2019-03-31 0.15 -3.37 4.12
2018-12-31 0.98 -3.88 4.07
2018-09-30 1.16 -3.72 4.01
2018-06-30 0.01 -3.57 4.35
2018-03-31 0.89 -3.29 4.03
2017-12-31 1.77 -3.01 3.72
2017-09-30 2.31 -2.36 3.49
2017-06-30 2.85 -1.71 3.27
2017-03-31 3.54 -0.83 3.11
2016-12-31 4.22 0.05 2.95
2016-09-30 3.33 -0.34 2.69
2016-06-30 2.45 -0.72 2.43
2016-03-31 1.34 -1.46 2.17
2015-12-31 0.23 -2.20 1.91
2015-09-30 0.14 -2.00 1.72
2015-06-30 0.06 -1.80 1.53
2015-03-31 0.05 -1.66 1.34
2014-12-31 0.05 -1.52 1.16
2014-09-30 0.07 -1.19 0.89
2014-06-30 0.09 -0.86 0.63
2013-06-30 0.09 -0.19 0.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Anatara Lifesciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Anatara Lifesciences has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Anatara Lifesciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Anatara Lifesciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anatara Lifesciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ANR Health

 How is Anatara Lifesciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anatara Lifesciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anatara Lifesciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anatara Lifesciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anatara Lifesciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Anatara Lifesciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anatara Lifesciences Company Filings, last reported 4 months ago.

ASX:ANR Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 5.92 0.00 5.41
2019-03-31 5.92 0.00 5.41
2018-12-31 6.66 0.00 6.06
2018-09-30 6.66 0.00 6.06
2018-06-30 8.59 0.00 7.65
2018-03-31 8.59 0.00 7.65
2017-12-31 10.39 0.00 8.54
2017-09-30 10.39 0.00 8.54
2017-06-30 12.02 0.00 10.86
2017-03-31 12.02 0.00 10.86
2016-12-31 13.21 0.00 11.77
2016-09-30 13.21 0.00 11.77
2016-06-30 13.48 0.00 13.82
2016-03-31 13.48 0.00 13.82
2015-12-31 12.83 0.00 12.88
2015-09-30 12.83 0.00 12.88
2015-06-30 5.48 0.00 5.55
2015-03-31 5.48 0.00 5.55
2014-12-31 6.49 0.00 6.47
2014-09-30 6.49 0.00 6.47
2014-06-30 0.83 0.00 1.05
2013-06-30 -0.28 0.35 0.07
  • Anatara Lifesciences has no debt.
  • Anatara Lifesciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Anatara Lifesciences has sufficient cash runway for 2.2 years based on current free cash flow.
  • Unable to confirm if Anatara Lifesciences has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Anatara Lifesciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anatara Lifesciences has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ANR Dividends

 What is Anatara Lifesciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anatara Lifesciences dividends.
If you bought A$2,000 of Anatara Lifesciences shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anatara Lifesciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anatara Lifesciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ANR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:ANR Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2024-06-30
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anatara Lifesciences has not reported any payouts.
  • Unable to verify if Anatara Lifesciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anatara Lifesciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anatara Lifesciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anatara Lifesciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anatara Lifesciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anatara Lifesciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ANR Management

 What is the CEO of Anatara Lifesciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Lydeamore
COMPENSATION A$625,510
TENURE AS CEO 0.9 years
CEO Bio

Mr. Steven Lydeamore, also known as Steve, MBA,CPA, has been the Chief Executive Officer of Anatara Lifesciences Limited since December 3, 2018. Mr. Lydeamore served as the Chief Financial Officer of Bionomics Limited since August 2017 until November 23, 2018. He served as President of Apobiologix. He served as the President of Global Specialty Pharma at Apotex Inc. since April 1, 2015. He served as Managing Director of International and Chief Business Officer of Apotex Inc. until April 1, 2015. He worked in various finance roles for F.H. Faulding & Co. Limited in Australia over a ten year period. He has 25 years' international pharmaceutical experience. Mr. Lydeamore served as Chief Business Officer and Managing Director of International at Apotex Inc. until April 1, 2015. Mr. Lydeamore served as Vice President of Business Development for Americas at Mayne Pharma (USA) Inc. He was employed at Mayne Pharma (USA) Inc. for four years. He is a Certified Practising Accountant. He has a B.Bus. (Appl. Ec.) from Deakin University and MBA from RMIT University.

CEO Compensation
  • Insufficient data for Steve to compare compensation growth.
  • Steve's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Anatara Lifesciences management team in years:

2.7
Average Tenure
  • The tenure for the Anatara Lifesciences management team is about average.
Management Team

Steve Lydeamore

TITLE
Chief Executive Officer
COMPENSATION
A$626K
TENURE
0.9 yrs

Mike West

TITLE
Chief Operating Officer
COMPENSATION
A$298K
AGE
55
TENURE
3.4 yrs

Tracey Brown

TITLE
Chief Development Officer
COMPENSATION
A$337K
AGE
56
TENURE
1.9 yrs

Jane Lowe

TITLE
Managing Director of IR Department

Steve Denaro

TITLE
Company Secretary
TENURE
5.8 yrs

Hayley van der Meer

TITLE
Commercial Manager
Board of Directors Tenure

Average tenure of the Anatara Lifesciences board of directors in years:

1.2
Average Tenure
  • The average tenure for the Anatara Lifesciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sue MacLeman

TITLE
Non-Executive Chairman
COMPENSATION
A$127K
AGE
55
TENURE
1.2 yrs

Jane Ryan

TITLE
Non-Executive Director
COMPENSATION
A$68K
TENURE
1.2 yrs

David Brookes

TITLE
Non-Executive Director
COMPENSATION
A$35K
AGE
59
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Anatara Lifesciences individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
04. Nov 19 Buy Jane Ryan Individual 01. Nov 19 01. Nov 19 49,745 A$0.19 A$9,482
01. Nov 19 Buy David Brookes Individual 01. Nov 19 01. Nov 19 50,000 A$0.20 A$9,750
10. Mar 19 Buy Susan MacLeman Individual 05. Mar 19 05. Mar 19 12,477 A$0.40 A$4,947
27. Feb 19 Buy David Brookes Individual 25. Feb 19 26. Feb 19 50,000 A$0.41 A$20,401
X
Management checks
We assess Anatara Lifesciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anatara Lifesciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ANR News

Simply Wall St News

Is Anatara Lifesciences Limited's (ASX:ANR) CEO Paid Enough Relative To Peers?

According to our data, Anatara Lifesciences Limited has a market capitalization of AU$11m, and pays its CEO total annual compensation worth AU$317k. … ASX:ANR CEO Compensation, August 19th 2019 Is Anatara Lifesciences Limited Growing? … Given the total loss of 79% over three years, many shareholders in Anatara Lifesciences Limited are probably rather dissatisfied, to say the least.

Simply Wall St -

What Kind Of Shareholder Appears On The Anatara Lifesciences Limited's (ASX:ANR) Shareholder Register?

Insider Ownership Of Anatara Lifesciences The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. … Private Company Ownership It seems that Private Companies own 16%, of the ANR stock.

Simply Wall St -

Loss-Making Anatara Lifesciences Limited (ASX:ANR) Expected To Breakeven

Check out our latest analysis for Anatara Lifesciences Expectation from Biotechs analysts is ANR is on the verge of breakeven. … This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. … For a more comprehensive look at ANR, take a look at ANR’s company page on Simply Wall St.

Simply Wall St -

These Fundamentals Make Anatara Lifesciences Limited (ASX:ANR) Truly Worth Looking At

In the case of ANR, it is a company with impressive financial health as well as a buoyant future outlook. … Flawless balance sheet with exceptional growth potential Investors in search for stocks with room to flourish should look no further than ANR, with its expected earnings growth of 79%. … ASX:ANR Past and Future Earnings, May 16th 2019 Next Steps: For Anatara Lifesciences, there are three key factors you should look at: Historical Performance: What has ANR's returns been like over the past?

Simply Wall St -

What Kind Of Shareholder Appears On The Anatara Lifesciences Limited's (ASX:ANR) Shareholder Register?

Generally speaking, as a company grows, institutions will increase their ownership. … With a market capitalization of AU$24m, Anatara Lifesciences is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Anatara Lifesciences

Simply Wall St -

If You Had Bought Anatara Lifesciences (ASX:ANR) Stock A Year Ago, You'd Be Sitting On A 67% Loss, Today

While not a mind-blowing move, it is good to see that the Anatara Lifesciences Limited (ASX:ANR) share price has gained 29% in the last three months. … We don't think Anatara Lifesciences's revenue of AU$978,546 is enough to establish significant demand. … When it last reported its balance sheet in December 2018, Anatara Lifesciences had net cash of AU$4.8m.

Simply Wall St -

Anatara Lifesciences Limited (ASX:ANR): Time For A Financial Health Check

The direct benefit for Anatara Lifesciences Limited (ASX:ANR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is ANR will have to adhere to stricter debt covenants and have less financial flexibility. … Does ANR's growth rate justify its decision for financial flexibility over lower cost of capital

Simply Wall St -

What Kind Of Shareholder Owns Most Anatara Lifesciences Limited (ASX:ANR) Stock?

Every investor in Anatara Lifesciences Limited (ASX:ANR) should be aware of the most powerful shareholder groups. … With a market capitalization of AU$21m, Anatara Lifesciences is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Anatara Lifesciences

Simply Wall St -

Who Are Anatara Lifesciences Limited's (ASX:ANR) Major Shareholders?

I am going to take a deep dive into Anatara Lifesciences Limited’s (ASX:ANR) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Anatara Lifesciences Limited (ASX:ANR): The Best Of Both Worlds

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as

Simply Wall St -

ANR Company Info

Description

Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastro intestinal diseases in animals and humans in Australia. Its lead product includes Detach, a non-antibiotic therapy that prevents and treats diarrhea disease in piglets. The company is also developing bromelain formulations for gastrointestinal health. Anatara Lifesciences Limited is based in Brisbane, Australia.

Details
Name: Anatara Lifesciences Limited
ANR
Exchange: ASX
Founded:
A$10,655,978
49,562,693
Website: http://www.anataralifesciences.com
Address: Anatara Lifesciences Limited
433 Logan Road,
Stones Corner,
Brisbane,
Queensland, 4120,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ANR Ordinary Shares Australian Securities Exchange AU AUD 16. Oct 2014
CHIA ANR Ordinary Shares Chi-X Australia AU AUD 16. Oct 2014
Number of employees
Current staff
Staff numbers
0
Anatara Lifesciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:43
End of day share price update: 2019/11/17 00:00
Last estimates confirmation: 2019/08/26
Last earnings filing: 2019/08/26
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.